C1S Stock Overview
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
China Shineway Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.03 |
| 52 Week High | HK$1.23 |
| 52 Week Low | HK$0.77 |
| Beta | 0.81 |
| 11 Month Change | -6.36% |
| 3 Month Change | 6.74% |
| 1 Year Change | 31.21% |
| 33 Year Change | 27.16% |
| 5 Year Change | 12.57% |
| Change since IPO | -21.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| C1S | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.3% | 1.6% | 1.1% |
| 1Y | 31.2% | -19.0% | 7.2% |
Return vs Industry: C1S exceeded the German Pharmaceuticals industry which returned -18.3% over the past year.
Return vs Market: C1S exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| C1S volatility | |
|---|---|
| C1S Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C1S has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: C1S's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 3,232 | n/a | www.shineway.com |
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products; and research and development of Chinese pharmaceutical products.
China Shineway Pharmaceutical Group Limited Fundamentals Summary
| C1S fundamental statistics | |
|---|---|
| Market cap | €804.91m |
| Earnings (TTM) | €144.27m |
| Revenue (TTM) | €549.17m |
5.6x
P/E Ratio1.5x
P/S RatioIs C1S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C1S income statement (TTM) | |
|---|---|
| Revenue | CN¥4.20b |
| Cost of Revenue | CN¥1.04b |
| Gross Profit | CN¥3.16b |
| Other Expenses | CN¥2.06b |
| Earnings | CN¥1.10b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.46 |
| Gross Margin | 75.21% |
| Net Profit Margin | 26.27% |
| Debt/Equity Ratio | 4.5% |
How did C1S perform over the long term?
See historical performance and comparison